|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.54 EUR | +1.26% |
|
+3.66% | -0.54% |
| 04-07 | California law limiting dialysis providers' profits voided by US appeals court | RE |
| 04-06 | Fresenius Medical Care AG announces Annual dividend, payable on May 27, 2026 | CI |
| Capitalization | 10.82B 12.66B 10B 9.43B 17.5B 1,170B 17.91B 118B 46.05B 564B 47.52B 46.51B 2,015B | P/E ratio 2026 * |
12.3x | P/E ratio 2027 * | 9.76x |
|---|---|---|---|---|---|
| Enterprise value | 19.03B 22.27B 17.6B 16.59B 30.79B 2,058B 31.49B 208B 80.98B 992B 83.57B 81.8B 3,544B | EV / Sales 2026 * |
0.97x | EV / Sales 2027 * | 0.9x |
| Free-Float |
67.83% | Yield 2026 * |
3.55% | Yield 2027 * | 3.93% |
Last Transcript: Fresenius Medical Care AG
| 1 day | +1.26% | ||
| 1 week | +3.66% | ||
| Current month | +5.11% | ||
| 1 month | +2.40% | ||
| 3 months | -0.25% | ||
| 6 months | -12.82% | ||
| Current year | -0.54% |
| 1 week | 38.81 |  | 40.64 |
| 1 month | 36.82 | | 40.64 |
| Current year | 35.67 | | 41.79 |
| 1 year | 35.67 | | 54.02 |
| 3 years | 30.16 | | 54.02 |
| 5 years | 25.95 | | 71.14 |
| 10 years | 25.95 | | 93.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Giza
CEO | Chief Executive Officer | 58 | 05/12/2022 |
Martin Fischer
DFI | Director of Finance/CFO | 49 | 30/09/2023 |
| Chief Tech/Sci/R&D Officer | 56 | 31/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 59 | 11/05/2016 |
A. Sorensen
BRD | Director/Board Member | 64 | 19/05/2021 |
Michael Sen
CHM | Chairman | 57 | 13/07/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.26% | +3.66% | -4.07% | -1.46% | 12.66B | |
| +0.41% | +7.49% | +49.82% | +87.44% | 113B | |
| +0.06% | +7.28% | +12.34% | +1.68% | 101B | |
| +0.45% | +3.31% | +22.07% | +75.78% | 29.32B | |
| -1.88% | -1.41% | -7.65% | -5.71% | 23.43B | |
| -0.53% | -0.17% | +18.56% | +17.69% | 22.52B | |
| -0.50% | -0.10% | +20.58% | +38.45% | 21.9B | |
| +0.94% | +3.04% | +41.20% | +87.25% | 17.81B | |
| +1.27% | +7.28% | +54.02% | +230.88% | 17.56B | |
| +0.60% | +6.33% | +2.63% | +46.69% | 11.48B | |
| Average | +0.20% | +3.56% | +20.95% | +57.87% | 37.11B | |
| Weighted average by Cap. | +0.16% | +5.19% | +26.66% | +52.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 19.56B 22.88B 18.08B 17.04B 31.63B 2,114B 32.35B 213B 83.2B 1,020B 85.85B 84.03B 3,641B | 20.34B 23.79B 18.8B 17.73B 32.89B 2,199B 33.65B 222B 86.53B 1,060B 89.29B 87.4B 3,787B |
| Net income | 901M 1.05B 833M 785M 1.46B 97.36B 1.49B 9.83B 3.83B 46.96B 3.95B 3.87B 168B | 1.12B 1.32B 1.04B 980M 1.82B 122B 1.86B 12.27B 4.79B 58.65B 4.94B 4.83B 209B |
| Net Debt | 8.21B 9.61B 7.59B 7.16B 13.28B 888B 13.59B 89.6B 34.94B 428B 36.05B 35.29B 1,529B | 7.5B 8.78B 6.94B 6.54B 12.14B 811B 12.42B 81.89B 31.93B 391B 32.95B 32.25B 1,397B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/04/26 | 40.54 € | +1.25% | 74,579 |
| 09/04/26 | 40.04 € | -0.52% | 474,396 |
| 08/04/26 | 40.25 € | +2.91% | 712,838 |
| 07/04/26 | 39.11 € | +1.14% | 701,073 |
| 02/04/26 | 38.67 € | +0.21% | 651,266 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- FME Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition